How would you approach a patient who progressed on immunotherapy for merkel cell carcinoma?
Checkpoint inhibitors have demonstrated durable responses in clinical trials, which was never seen with cytotoxic chemotherapy in the past. What are the second line options for patients who unfortunately fail to respond to immunotherapy?
1 Answer
Mednet Member
Medical Oncology · Sediman Cancer Center/University Hospitals of Cleveland Case Medical Center
Answered on · Updated on
This is an excellent question in a rare disease where we have clearly seen the use of immunotherapy leap to the forefront of management. Based on the Javelin II (previously treated patients) data, the FDA approved the use of Avelumab for patients with advanced MCC regardless of prior therapy in May ...
Join for free or sign in to see the full answer